methyl 4-{(1S)-1-[(2,3-dihydro-1H-indol-7-ylcarbonyl)amino]ethyl}benzoate | 960240-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 4-{(1S)-1-[(2,3-dihydro-1H-indol-7-ylcarbonyl)amino]ethyl}benzoate
• 英文别名: Benzoic acid,4-[(1s)-1-[[(2,3-dihydro-1h-indol-7-yl)carbonyl]amino]ethyl]-,methyl ester；methyl 4-[(1S)-1-(2,3-dihydro-1H-indole-7-carbonylamino)ethyl]benzoate
• CAS: 960240-25-9
• 化学式: C₁₉H₂₀N₂O₃
• 分子量: 324.379
• InChiKey: IGFVDUFGCSFVKR-LBPRGKRZSA-N

物化性质

• 沸点：
  517.2±50.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-{(1S)-1-[(2,3-dihydro-1H-indol-7-ylcarbonyl)amino]ethyl}benzoate 在 氢氧化钾 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 4.0h， 生成 4-[(1S)-1-({[1-(3-chlorobenzyl)-2,3-dihydro-1H-indol-7-yl]carbonyl}amino)ethyl]benzoic acid - potassium salt
  参考文献：
  名称：

  WO2007/143825

  摘要：

  公开号：
• 作为产物：
  描述：

  N-Boc-吲哚啉-7-羧酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 3.0h， 生成 methyl 4-{(1S)-1-[(2,3-dihydro-1H-indol-7-ylcarbonyl)amino]ethyl}benzoate
  参考文献：
  名称：

  WO2007/143825

  摘要：

  公开号：

文献信息

• Indole Amide Derivatives as Ep4 Receptot Ligands
  申请人：Boyd Michael

  公开号：US20090105321A1

  公开（公告）日：2009-04-23

  The invention is directed to indoline amide derivatives as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.

  本发明涉及吲哚啉酰胺衍生物作为EP4受体配体，拮抗剂或激动剂，用于治疗EP4介导的疾病或病状，例如急性和慢性疼痛，骨关节炎，类风湿性关节炎，癌症和青光眼。还包括药物组合物和使用方法。
• Indoline amide derivatives as EP4 receptor ligands
  申请人：Merck Frosst Canada Ltd.

  公开号：US07705035B2

  公开（公告）日：2010-04-27

  The invention is directed to indoline amide derivatives of formula I as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.

  该发明涉及公式I的吲哚酰胺衍生物，作为EP4受体配体，用于治疗EP4介导的疾病或病状，例如急性和慢性疼痛、骨关节炎、类风湿性关节炎、癌症和青光眼。还包括药物组合物和使用方法。
• AMIDE COMPOUNDS
  申请人：Nozawa Eisuke

  公开号：US20110028463A1

  公开（公告）日：2011-02-03

  [Problems] To provide a compound that is useful as an agent for treating chronic renal insufficiency or an agent for treating diabetic nephropathy. [Means for Solving Problems] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic action, and as a result, they have found that various amide derivatives having a carboxylic group or an equivalent thereof exhibit an excellent EP4 receptor antagonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor antagonistic action, it is useful as an agent for preventing and/or treating chronic renal insufficiency or diabetic nephropathy.

  【问题】提供一种可用作治疗慢性肾功能不全或糖尿病肾病的药物化合物。 【解决问题的方法】本发明者对具有EP4受体拮抗作用的化合物进行了广泛的研究，结果发现具有羧酸基或其等效物的各种酰胺衍生物表现出优异的EP4受体拮抗作用，从而完成了本发明。由于本发明的化合物具有优异的EP4受体拮抗作用，因此可用作预防和/或治疗慢性肾功能不全或糖尿病肾病的药物。
• A novel series of potent and selective EP4 receptor ligands: Facile modulation of agonism and antagonism
  作者：Michael J. Boyd、Carl Berthelette、Jean-François Chiasson、Patsy Clark、John Colucci、Danielle Denis、Yongxin Han、Jean-Francois Lévesque、Marie-Claude Mathieu、Rino Stocco、Alex Therien、Steve Rowland、Mark Wrona、Daigen Xu

  DOI：10.1016/j.bmcl.2010.10.106

  日期：2011.1

  A novel series of EP4 ligands, based on a benzyl indoline scaffold, has been discovered. It was found that agonism and antagonism in this series can be easily modulated by minor modifications on the benzyl group. The pharmacokinetic, metabolic and pharmacological profiles of these compounds was explored. It was found that these compounds show good pharmacokinetics in rat and are efficacious in pre-clinical models of pain and inflammation. (c) 2010 Elsevier Ltd. All rights reserved.
• INDOLINE AMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS
  申请人：Merck Canada Inc.

  公开号：EP2035376B1

  公开（公告）日：2014-08-27